The U.S. Food and Drug Administration (FDA) recently approved Leqembi, a drug indicated to treat Alzheimer’s disease in patients with mild cognitive impairment. The FDA granted Leqembi an Accelerated ...

"Early ultrastructural investigations showed a prominent presence of degenerating mitochondria in the brain of patients with ...

A recent review published in Molecular and Cellular Neuroscience suggests that a popular class of diabetes and weight-loss ...

A recent study suggests that newly developed blood tests can accurately detect signs of Alzheimer’s disease in adults with ...

New studies point to the power of testing for and treating tau, a protein that builds up in Alzheimer’s disease, instead of just amyloid.

How can Alzheimer's research be made faster, better, and more effective? After decades of intensive research worldwide and despite recent therapeutic advances, scientists have not managed to fully ...

Alzheimer's researchers discovered a third plaque type forming inside neurons that may appear before amyloid - and could become a new treatment target.

A new study shows ImmunoBrain anti-PD-L1 antibody IBC-Ab002 is safe and reduces neurodegenerative biomarkers in Alzheimer's.

Researchers created a 3D human brain tissue model using stem cells to model Alzheimer's plaque clearance and enable automated ...

Rather than target amyloid plaques, the potential new treatment aims to restore immune functions that naturally decline with age.

COVID-19 may increase the risk of Alzheimer’s disease, especially for those who experience a severe infection. COVID-19 causes inflammation and other physiological changes in the brain that are ...

In 3,895 older adults, moderate daytime cortisol variability was associated with better cognition and slower decline, while ...